More critically, by inhibiting IL-4 mRNA expression in the livers of patients with PC malignancy (119) and by improving the physical condition of IL-4-treated tumor-bearing mice (120), it may provide a potentially effective approach for the future treatment of PC patients with tumor-induced malignancy. The gene discussed is IL4; the disease is pachyonychia congenita.